Clinical Trials on Blood Protein Disorders

Total 201099 results

Johnson & Johnson Pharmaceutical Research & Development...
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Myeloma | M-Protein | Myeloma Proteins
Takeda

Active, not recruiting

A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency

Congenital Protein C Deficiency

Japan
University Hospital, Geneva
Hospices Civils de Lyon

Not yet recruiting

Biomarker-s of Abusive Head Trauma by Proteomics

Abuse, Child | Protein Disorder, Blood

France, Switzerland
University Hospital, Strasbourg, France

Recruiting

Interference by Activated Protein C Resistance in the Determination of Protein S Activity (PS)

Resistance to Activated Protein C in the Determination of Protein S Activity

France
University of Arkansas
University of Iowa

Not yet recruiting

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders

Plasma Cell Disorder
University of Aarhus

Unknown

Ghrelin Levels in Patients With Protein C Deficiency

Protein C Deficiency
Baxalta now part of Shire
American Thrombosis and Hemostasis Network; UDC Rare Bleeding and Clotting...

Completed

Ceprotin Treatment Registry

Protein C Deficiency

United States, United Kingdom, Germany, Italy, Netherlands, Austria
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency

Protein C Deficiency

United States
Becton, Dickinson and Company

Completed

Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer

Plasma Cell Disorder

Switzerland, Spain, United Kingdom, United States, Portugal
Akron Children's Hospital

Completed

Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients

Hypoalbuminemia

United States
Universiti Putra Malaysia

Completed

Effect of Resistance Training in Water Combined With Land on Starting and Turning ,12-weeks Resistance Training

Resistance, APC

China
Semarang Health Polytechnic

Unknown

NutFish and Nutrient Supplementation in Pregnancy Class to Improve Maternal and Birth Outcomes

Anemia | Pregnancy | Protein-Energy Malnutrition

Indonesia
Baxalta now part of Shire

Completed

Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND

Protein C Deficiency

United States
Siriraj Hospital
Faculty of Medicine Siriraj Hospital

Not yet recruiting

Registry of Patients With Plasma Cell Disorders (Registry PCD)

Plasma Cell Disorders
Hamilton Health Sciences Corporation

Completed

Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial (FADE)

Edema | Hypoproteinemia

Canada
Technical University of Munich

Completed

SUbstition of PERioperative Albumin Deficiency Disorders (SUPERADD)

Hypoalbuminemia

Germany
Wageningen University
Top Institute Food and Nutrition

Completed

Study to Identify Biomarkers for Protein Intake (Biomarker)

Identify New Biomarkers in Blood or Urine After Consumption of Meat Protein, Dairy Protein and Grain Protein in Healthy Subjects.

Netherlands
Zhujiang Hospital

Recruiting

A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.

Multiple Myeloma | M Protein

China
Siriraj Hospital

Not yet recruiting

Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing (genetics MM)

Plasma Cell Disorder
Prometic Biotherapeutics, Inc.

Completed

A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia

Hypoplasminogenemia | Congenital Plasminogen Deficiency

United States, Norway
Lundquist Institute for Biomedical Innovation at...
Abbott Nutrition; DaVita Dialysis

Completed

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients (AIONID)

Inflammation | Oxidative Stress | Hypoalbuminemia | Protein-energy Malnutrition | Chronic Kidney Disease (CKD) Hemodialysis

United States
Cogent Biosciences, Inc.

Terminated

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

Multiple Myeloma | Solid Tumor | HER-2 Protein Overexpression | B Cell Lymphomas

United States
An Hsin QingShui Clinic

Completed

Dialysis Model for Outcome and Nutrition Decision (DIAMOND)

Protein-Calorie Malnutrition

Taiwan
The University of Texas Health Science Center,...

Withdrawn

Changes in Bleeding and Clotting During the Menstrual Cycle

Healthy | Von Willebrand's Disorder

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Multicenter Randomized Double-blind Study Comparing the Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis) (TRIBECA)

Vasculitis | Cryoglobulinemia
Prometic Biotherapeutics, Inc.

Completed

A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency

Hypoplasminogenemia | Type I Plasminogen Deficiency

United States
Zhujiang Hospital
National Natural Science Foundation of China

Recruiting

Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis

Multiple Myeloma | Monoclonal Gammopathies | M-protein

China
BioMarin Pharmaceutical

Active, not recruiting

Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 (GENEr8-AAV5+)

Hemophilia A | Gene Therapy | Blood Disorder | Clotting Disorders

Taiwan, Korea, Republic of, United Kingdom, South Africa
Regeneron Pharmaceuticals

Active, not recruiting

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

CD55-deficient Protein-losing Enteropathy | CHAPLE

United States, Thailand, Turkey
Centre Hospitalier Universitaire, Amiens
Binding site

Recruiting

The Distribution of Immunoglobulin Isotype in Polyclonal Hypergammaglobulinemia in Systemic and Autoimmune Diseases (ISOHYPE)

Autoimmune Diseases | Polyclonal Hypergammaglobulinemia

France
University Hospital, Clermont-Ferrand

Unknown

Acid Base Balance of ICU Patients With Severe Hypoalbuminemia, Before and After an Albumin Infusion, Using Stewart Approach (STEWALB)

Hypoalbuminemia | Adult ICU Patient | Stewart Approach for Acid Base Disorders | Human Albumin Perfusion

France
Cedars-Sinai Medical Center

Completed

Stepping Up: A Trial of Activity Monitoring Devices in Patients Undergoing Autologous Stem Cell Transplant

Lymphoma | Multiple Myeloma | Transplant-Related Disorder

United States
Mayo Clinic
Arizona State University

Completed

Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma

Multiple Myeloma | Plasma Cell Disorder

United States
French National Agency for Research on AIDS and...

Completed

Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients

Cryoglobulinemia Vasculitis

France
Spark Therapeutics

Completed

Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors

Hematologic Diseases | Blood Coagulation Disorders, Inherited | Coagulation Protein Disorders | Hemorrhagic Disorders | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Gene Therapy | Blood Coagulation Disorder | Gene Transfer | Adeno-Associated Virus (AAV) | Factor VIII (FVIII) | Factor VIII (FVIII)... and other conditions

United States
University of Colorado, Denver

Completed

Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

Hyperphosphatemia | Hypoalbuminemia | Peritoneal Dialysis Complication

United States
Novo Nordisk A/S

Completed

Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

Congenital Bleeding Disorder | Haemophilia A

Mexico
Novo Nordisk A/S

Terminated

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (explorer™2)

Healthy | Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United Kingdom, France, Germany
Novo Nordisk A/S

Completed

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A (guardian ™9)

Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United States, Germany, Serbia, Taiwan, Bulgaria
Novo Nordisk A/S

Completed

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A (pathfinder™7)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Germany, France, Denmark
Maastricht University Medical Center
DSM Food Specialties

Recruiting

Impact of Canola Protein Processing on Plasma Amino Acid Responses (CANOLAA)

Protein Metabolism Disorder

Netherlands
Novo Nordisk A/S

Completed

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A (pathfinder8)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Switzerland, Taiwan, Turkey, United Kingdom, Croatia, Germany, Brazil, France, Japan, Australia, Hungary, Israel, Korea, Republic of, Lithuania, Portugal, Ukraine, Greece, Italy, Denmark, Norway, Canada and more
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A (guardian™4)

Congenital Bleeding Disorder | Haemophilia A

United States, Denmark, Austria, Spain, Japan, Brazil, Algeria, Lithuania, Portugal, Russian Federation, Serbia, Turkey, Greece, Hong Kong, Puerto Rico, Hungary, China, Poland
Novo Nordisk A/S

Completed

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A (pathfinder™5)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Switzerland, Malaysia, Brazil, Canada, Japan, United Kingdom, Israel, Portugal, Ukraine, Greece, Lithuania, Puerto Rico, Turkey, Italy
Novo Nordisk A/S

Completed

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. (pathfinder™3)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, United Kingdom, Croatia, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Italy, Japan, Norway, Bulgaria
Novo Nordisk A/S

Completed

Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A (alleviate 1)

Congenital Bleeding Disorder | Haemophilia A

United States, Austria, Serbia, Germany, Japan, France
Novo Nordisk A/S

Completed

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 (mentor™2)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

France, United States, Israel, Spain, Switzerland, Germany, Canada, Japan, United Kingdom, Italy, Finland, Austria
Novo Nordisk A/S

Completed

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Austria, Spain, Poland, United Kingdom, Croatia, Germany, Malaysia, Australia, France, Israel, Thailand, Ukraine, Turkey
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A (guardian™ 3)

Congenital Bleeding Disorder | Haemophilia A

United States, Macedonia, The Former Yugoslav Republic of, Serbia, Malaysia, Brazil, Turkey, Lithuania, Russian Federation, Italy, Japan, Poland, Puerto Rico, Taiwan
Novo Nordisk A/S

Completed

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

Congenital Bleeding Disorder | Haemophilia A

Japan

Clinical Trials on Blood Protein Disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations